Rabeximod

DB05772InvestigationalSmall molecule

Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

Primary indication: Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
Formula / weight: C₂₂H₂₄ClN₅O · 409.92 g/mol (avg)
Code names: ROB-803

Resolves to

Compound

UNIIJ4D3K58W3ZCAS872178-65-9PubChem56841552

Structure

InChIKeyPDNNUMNEXITLCZ-UHFFFAOYSA-NSMILESCN(C)CCNC(=O)CN1C2=CC=C(Cl)C=C2C2=C1N=C1C=C(C)C(C)=CC1=N2

What you can answer from here — as of February 21, 2021

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Rabeximod, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account